Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open-Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects With Advanced Solid Tumours

NCT03733990 is registered in ClinicalTrials.gov with Faron Pharmaceuticals Ltd as lead sponsor.

NCT NCT03733990
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03733990 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open-Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects With Advanced Solid Tumours
Lead sponsor
Faron Pharmaceuticals Ltd
Phase
Phase 1/2
Overall status
Completed
Start date
December 3, 2018
Completion date
October 31, 2023
Enrollment
216 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

cancer